Inmunómica traslacional en neoplasias hematológicas
Karmanos Cancer Institute
Detroit, Estados UnidosPublications in collaboration with researchers from Karmanos Cancer Institute (2)
2020
-
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
Leukemia, Vol. 34, Núm. 12, pp. 3298-3309
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557